

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

ENTROPHEN[®]

acetylsalicylic acid delayed release tablets

Tablets (Delayed-Release), 81 mg, Oral

USP

Platelet aggregation inhibitor

**PENDOPHARM, Division of
Pharmascience Inc.**

6111 Royalmount Ave., Suite 100
Montréal, Québec H4P 2T4

Date of Authorization: FEB 25, 2025

Submission Control Number: 290185

[®] Registered trademark owned of Norwell consumer Healthcare Inc

TABLE OF CONTENTS

TABLE OF CONTENTS	2
1 INDICATIONS	4
1.1 Pediatrics	4
1.2 Geriatrics	4
2 CONTRAINDICATIONS	5
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	5
4 DOSAGE AND ADMINISTRATION	5
4.1 Dosing Considerations	5
4.2 Recommended Dose and Dosage Adjustment.....	5
4.4 Administration	6
4.5 Missed dose.....	6
5 OVERDOSAGE	6
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	7
7 WARNINGS AND PRECAUTIONS	8
7.1 Special Populations	9
7.1.1 Pregnant Women	9
7.1.2 Breast-feeding	11
7.1.3 Pediatrics	11
7.1.4 Geriatrics	11
8 ADVERSE REACTIONS	11
8.1 Adverse Reaction Overview	11
9 DRUG INTERACTIONS	12
9.2 Drug Interactions Overview	12
9.3 Drug-Behavioural Interactions	12
9.4 Drug-Drug Interactions	12
9.5 Drug-Food Interactions	14
9.6 Drug-Herb Interactions	14
9.7 Drug-Laboratory Test Interactions	14
10 CLINICAL PHARMACOLOGY	14
10.1 Mechanism of Action.....	14
10.2 Pharmacodynamics	15
10.3 Pharmacokinetics	18

11	STORAGE, STABILITY AND DISPOSAL	19
12	SPECIAL HANDLING INSTRUCTIONS	19
	PART II: SCIENTIFIC INFORMATION	20
13	PHARMACEUTICAL INFORMATION	20
14	CLINICAL TRIALS	21
14.1	Trial Design and Study Demographics.....	21
14.2	Study Results	23
15	MICROBIOLOGY	25
16	NON-CLINICAL TOXICOLOGY	25
17	SUPPORTING PRODUCT MONOGRAPHS	26
	PATIENT MEDICATION INFORMATION	27

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

ENTROPHEN is indicated for the following uses, based on its platelet aggregation inhibitory properties:

- for reducing the risk of vascular mortality in patients with a suspected acute myocardial infarction;
- for reducing the risk of a **first** non-fatal myocardial infarction in individuals deemed to be at sufficient risk of such an event by their physician.
 - There is no evidence for a reduction in the risk of **first** fatal myocardial infarction.
 - ENTROPHEN does not reduce the risk of either cardiovascular mortality or **first** strokes, fatal or non-fatal.
 - The decrease in the risk of **first** non-fatal myocardial infarction must be assessed against a much smaller but not insignificant increase in the risk of haemorrhagic stroke as well as gastrointestinal bleeding.
- for reducing the risk of morbidity and death in patients with unstable angina and in those with previous myocardial infarction
- for reducing the risk of transient ischemic attacks (TIA) and for secondary prevention of atherothrombotic cerebral infarction;
- for prophylaxis of venous thromboembolism after total hip replacement;

1.1 Pediatrics

Pediatrics (under 12): Based on the data submitted and reviewed by Health Canada for certain uses (See [4.2 DOSING](#)), the safety and efficacy of ASA in pediatric patients has been established. However, a possible association between Reye's syndrome and the use of salicylates has been suggested but not established. ASA should not be used in children and teenagers for viral infections with or without fever without consulting a physician. (See [7 WARNINGS AND PRECAUTIONS](#)).

1.2 Geriatrics

Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. (See [7 WARNINGS AND PRECAUTIONS](#)) In general, ASA should be used with caution in elderly patients (≥ 60 years of age), as these patients may be more susceptible to adverse reactions.

2 CONTRAINDICATIONS

ENTROPHEN is contraindicated in patients who are/have:

- Hypersensitive to ASA, salicylates, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, antipyretics or other ingredients in the product or component of the container. For a complete listing, see [6 DOSAGE FORMS, COMPOSITION AND PACKAGING](#) of the product monograph.
- Acute gastrointestinal ulcer
- History of gastrointestinal ulcers
- Hemorrhagic diathesis
- Active or Severe hepatic failure, renal failure, or congestive heart failure
- History of asthma induced by the administration of salicylates or substances with a similar action, notably NSAIDs
- Concomitant treatment with methotrexate at doses of 15mg/week or more (see [9 DRUG INTERACTIONS](#)).
- The third trimester of pregnancy, because of risk of premature closure of the ductus arteriosus, and prolonged parturition. (see [7.1 SPECIAL POPULATIONS](#))

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Risk in Pregnancy: Caution should be exercised in prescribing ENTROPHEN during the first and second trimesters of pregnancy. Use of NSAIDs at approximately 20 weeks of gestation or later may cause oligohydramnios, and renal dysfunction including renal failure (see [7 WARNINGS AND PRECAUTIONS](#)). ENTROPHEN is CONTRAINDICATED for use during the third trimester because of risk of premature closure of the ductus arteriosus and uterine inertia (prolonged parturition) (see [2 CONTRAINDICATIONS](#)).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- Please see below for specific dosing instructions for each indication.

4.2 Recommended Dose and Dosage Adjustment

- **Platelet aggregation inhibitor:**
 - **Suspected Acute Myocardial Infarction:**

An initial dose of at least 162 mg chewed to ensure rapid absorption as soon as a myocardial infarction is suspected. The same dose should be given as maintenance over the next 30 days. After 30 days, consider further therapy based on dosage and administration for prevention of recurrent MI (see Prior Myocardial Infarction).

- **Prevention of a first non-fatal myocardial infarction:**
81 – 325 mg once daily, according to the individual needs of the patient, as determined by the physician.
- **Prior Myocardial Infarction or Unstable Angina Pectoris:**
81 – 325 mg daily according to the individual needs of the patient, as determined by the physician.
- **Transient Ischemic Attack and Secondary Prevention of Atherothrombotic Cerebral Infarction:**
81 – 325 mg daily according to the individual needs of the patient, as determined by the physician.
- **Prophylaxis of Venous Thromboembolism after total hip replacement:**
162 – 325 mg daily according to the individual needs of the patient, as determined by the physician.

4.4 Administration

ENTROPHEN tablets should preferably be taken after meals, with plenty of liquid.

4.5 Missed dose

Take the missed dose as soon as you remember. But do not take an extra dose to compensate for a missed dosage unless instructed by your doctor.

5 OVERDOSAGE

Mild Overdose or Early Poisoning - burning in the mouth, lethargy, nausea, vomiting, tinnitus, sweating, thirst, tachycardia or dizziness.

Moderate Overdose - all of the symptoms from mild overdose plus tachypnea, hyperpyrexia, sweating, dehydration, loss of coordination, restlessness, mental confusion.

Severe Overdose - all of the symptoms from moderate overdose plus hypotension, hallucinations, stupor, hypoglycemia, convulsions, cerebral edema, oliguria, renal failure, cardiovascular failure, coma, hemorrhage, metabolic acidosis, respiratory alkalosis and/or failure.

Emergency Management:

1. Immediate transfer to hospital and maintain cardiovascular and respiratory support.
2. Gastric lavage, administration of activated charcoal,
3. Check of acid-base balance and correct if necessary.
4. Alkaline diuresis so as to obtain urine pH between 7.5 and 8 should be considered when plasma salicylate concentration is greater than 500 mg/L (3.6 mmol/L) in adults or 300 mg/L (2.2 mmol/L) in children

5. Hemodialysis should be considered in severe poisoning 800 mg/L (5.8 mmol/L) in adults and 700 mg/L (5.0 mmol/L) in children, as renal elimination of salicylates may be slow due to the presence of acidic urine and renal failure. Hemodialysis should also be considered if the patient is experiencing severe systemic metabolic acidosis (arterial pH < 7.2), acute renal failure, pulmonary edema or CNS symptoms such as: drowsiness, agitation, coma or convulsions.
6. Fluid losses should be replaced with hypotonic solution (e.g. half saline) and supplemented with glucose 50 to 100g/L.
7. Symptomatic treatment.

Fatal Dose: varies from 10 to 30g of ASA. However, (in one case) 130g of ASA was ingested without fatal outcome.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	ENTROPHEN: Round, white to off-white, film-coated tablet, 81mg acetylsalicylic acid	Colloidal Silicon Dioxide, Glyceryl Stearate, Lactose Anhydrous, Methacrylic Acid Copolymer, Methylated Silica, Methylcellulose, Polydimethylsiloxane, Polysorbate 65, Pregelatinized Starch, Sodium Bicarbonate, Sodium Lauryl Sulphate, Sorbic Acid, Stearic Acid, Sulfuric Acid, Talc, Titanium Dioxide and Triethyl Citrate.

ENTROPHEN: are packaged in bottles of 30, 120, 150, 180, 225, 255, 300, 360, 365, 500 and 1000 (for dispensing use only) tablets.

7 WARNINGS AND PRECAUTIONS

General

ASA is one of the most frequent causes of accidental poisonings in toddlers and infants. Tablets should be kept well out of the reach of children.

ASA should be administered cautiously to patients with:

- Uncontrolled hypertension
- Impaired hepatic, renal function or cardiovascular circulation (e.g., Renal vascular disease, congestive heart failure, volume depletion, major surgery, sepsis or major haemorrhagic events)
- A history of bleeding tendencies, significant anemia and/or hyp thrombinemia
- Concomitant treatment with anticoagulants (see [9.4 Drug-Drug Interactions](#))
- Concomitant treatment with NSAIDS, such as ibuprofen and naproxen in patients on an ASA regimen (see [9.4 Drug-Drug Interactions](#))

Hematologic

Due to effect on platelet aggregation, ASA may be associated with an increased risk of bleeding. Caution is necessary when salicylates and anticoagulants are prescribed concurrently, as salicylates can depress the concentration of prothrombin in the plasma.

Immune

ASA may precipitate bronchospasm and induce asthma attacks or other hypersensitivity reactions. Risk factors are present bronchial asthma, hay fever, nasal polyps, or chronic respiratory disease. This applies also for patients showing allergic reactions (e.g., cutaneous reactions, itching, urticaria) to other substances.

Monitoring and Laboratory Tests

Salicylates can produce changes in thyroid function tests.

Isolated cases of liver function disturbances (transaminases increase) have been described.

Pregnancy: If ENTROPHEN is administered in the middle (approximately 20 weeks) to the end of the second trimester, it is recommended that pregnant women on ENTROPHEN be closely monitored for amniotic fluid volume since ENTROPHEN may result in reduction of amniotic fluid volume and even oligohydramnios (see Special Populations). ENTROPHEN is CONTRAINDICATED for use in the third trimester of pregnancy.

Antenatal monitoring for ductus arteriosus constriction should be considered after exposure to acetyl salicylic acid from gestational week 20 onward. Treatment with acetyl salicylic acid should be discontinued if ductus arteriosus constriction is found.

Peri-Operative Considerations

Due to its inhibitory effect on platelet aggregation which persists for several days after administration, ASA may lead to an increased bleeding tendency during and after surgical operations (including minor surgeries, e.g., dental extractions).

Reproductive Health: Female and Male Potential

- **Fertility**

Based on the limited published data available, the studies in humans showed no consistent effect of acetylsalicylic acid on impairment of fertility and there is no conclusive evidence from animal studies

7.1 Special Populations

Low Uric Acid Excretion:

At low doses, ASA reduces excretion of uric acid. This can trigger gout in patients who already tend to have low uric acid excretion.

Glucose-6-phosphate dehydrogenase (G6PD) Deficiency:

In patient suffering from glucose-6-phosphate dehydrogenase (G6PD) deficiency, ASA may induce hemolysis or haemolytic anemia. Factors that may increase the risk of haemolysis are high dosage, fever, or acute infections.

7.1.1 Pregnant Women

Women attempting to conceive:

Based on the limited published data available, the studies in humans showed no consistent effect of acetylsalicylic acid on impairment of fertility and there is no conclusive evidence from animal studies.

Pregnant Women:

During the first and second trimester of pregnancy, acetylsalicylic acid containing drugs should not be given unless clearly necessary. If acetylsalicylic acid containing drugs are used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and duration of treatment as short as possible.

Oligohydramnios/Neonatal Renal Impairment:

Use of NSAIDs, including ENTROPHEN, at approximately 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some more severe cases, neonatal respiratory, musculoskeletal and renal problems.

Published studies and post-marketing reports describe maternal NSAID use at approximately 20 weeks gestation or later in pregnancy associated with fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment, or failure. NSAIDs were shown to cause significant reduction in fetal urine production prior to reduction of amniotic fluid volume. There have also been a limited number of case reports of maternal NSAID use and neonatal renal dysfunction without oligohydramnios, some of which were irreversible,

even after treatment discontinuation.

These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some post-marketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If, after careful consideration of alternative treatment options for pain management, NSAID treatment is necessary anywhere from the middle (onset approximately 20 weeks) to the end of the second trimester of pregnancy, it is recommended that the use be limited to the lowest effective dose and shortest duration possible.

Consider ultrasound monitoring of fetal well-being, including of amniotic fluid volume assessment if ENTROPHEN treatment extends beyond 48 hours. It is recommended that NSAIDs treatment be discontinued if oligohydramnios occurs, followed by appropriate medical follow up.

Inform pregnant women not to use ENTROPHEN and other NSAIDs from the third trimester of pregnancy because of the risk of the premature closing of the fetal ductus arteriosus. If treatment with ENTROPHEN is needed for a pregnant woman anywhere from the middle (onset approximately 20 weeks gestation) to the end of the second trimester of pregnancy, advise her that she may need to be monitored for oligohydramnios, if treatment continues for longer than 48 hours.

Also, there have been reports of ductus arteriosus constriction following treatment in the second trimester, most of which resolved after treatment cessation. Antenatal monitoring for ductus arteriosus constriction should be considered after exposure to acetyl salicylic acid from gestational week 20 onward. Treatment with acetyl salicylic acid should be discontinued if ductus arteriosus constriction is found.

Acetylsalicylic acid inhibits prostaglandin synthesis. Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/fetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-fetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period—Data from epidemiological studies raise concern about an increased risk of miscarriage and of malformations after the use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy. Available data do not support any association between intake of acetylsalicylic acid and an increased risk for miscarriage. For acetylsalicylic acid the available epidemiological data regarding malformation are not consistent, but an increased risk of gastroschisis could not be excluded. A prospective study with exposure in early pregnancy (1st-

4th month) of about 14,800 mother-child pairs has not yielded any association with an elevated rate of malformations.

- **During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:** Cardiopulmonary toxicity (Constriction/premature closure of the ductus arteriosus and pulmonary hypertension); Renal dysfunction, which may progress to renal failure with oligo-hydroamniosis.

Use of any prostaglandin synthesis inhibitors at the end of pregnancy may expose the mother and the child to:

Possible prolongation of bleeding time, an anti-aggregating effect which may occur even after very low doses; Inhibition of uterine contractions resulting in delayed or prolonged labour. Consequently, acetylsalicylic acid is contraindicated in the third trimester of pregnancy.

7.1.2 Breast-feeding

ASA and its metabolites pass into breast milk in small quantities. Since no adverse effects on the infant have been observed after occasional use, interruption of breast-feeding is usually unnecessary. However, on regular use or on intake of high doses, breast feeding should be discontinued early.

7.1.3 Pediatrics

A possible association between Reye's syndrome and the use of salicylates has been suggested but not established. Reye's syndrome has also occurred in many patients not exposed to salicylates. ASA should not be used in children and teenagers for viral infections with or without fever without consulting a physician. In certain viral illnesses, especially influenza A, influenza B and varicella, there is a risk of Reye's syndrome, a very rare but possibly life-threatening illness requiring immediate medical action. The risk may be increased when ASA is given concomitantly; however, no causal relationship has been proven. Should persistent vomiting occurs with such diseases; this may be a sign of Reye's syndrome.

7.1.4 Geriatrics

In general, ASA should be used with caution in elderly patients (≥ 60 years of age), as these patients may be more susceptible to adverse reactions.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Many adverse reactions due to ASA ingestion are dose-related. The following is a list of adverse reactions that have been reported in the literature and from both clinical and post-marketing experience.

Gastrointestinal: (the frequency and severity of these adverse effects are dose-related): nausea, vomiting, diarrhea, gastrointestinal bleeding and/or ulceration, dyspepsia, heartburn, hematemesis, melena, abdominal pain, rarely gastrointestinal inflammation, and intestinal diaphragm disease with frequency not known (especially in long-term treatment).

Bleeding: Due to platelet inhibition, bleedings e.g., perioperative haemorrhage, hematomas, epistaxis, urogenital bleedings, and gingival bleedings may occur.

Serious bleedings, such as gastrointestinal tract hemorrhages, and cerebral hemorrhages are rare. Isolated cases of potentially life-threatening bleedings have been reported, especially in patients with uncontrolled hypertension and/or concomitant antihemostatic agents.

Ear: dizziness, tinnitus, vertigo, hearing loss. Dizziness and tinnitus have been reported, which may be indicative of an overdose.

Hematologic: leukopenia, thrombocytopenia, purpura, anemia. Anemia with respective laboratory and clinical signs and symptoms, such as asthenia, pallor, and hypoperfusion is generally caused by bleeding (e.g., occult microbleeding, acute or chronic bleeding). Hemolysis and hemolytic anemia in patients with severe forms of glucose-6-phosphate dehydrogenase (G6PD) deficiency has been reported.

Dermatologic and hypersensitivity: urticaria, pruritus, skin eruptions, asthma, anaphylaxis, edema nasal congestion and rhinitis. Severe allergic reactions, including anaphylactic shock are very rarely reported.

Miscellaneous: mental confusion, drowsiness, sweating, thirst. Transient hepatic impairment with increase in liver transaminases has very rarely been reported. Renal impairment and acute renal failure have been reported.

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

ASA should be used with caution with other products that have anticoagulation or antiplatelet effects, as these effects may be potentiated. Drugs that bind to protein binding sites should also be used cautiously since ASA may displace drugs from their protein binding site.

9.3 Drug-Behavioural Interactions

Alcohol: Increased damage to gastrointestinal mucosa and prolonged bleeding time due to additive effects of acetylsalicylic acid and alcohol. Patients having 3 or more alcoholic drinks per day should consult their physician before use.

9.4 Drug-Drug Interactions

Methotrexate, used at doses of 15mg/week or more: Increased hematological toxicity of methotrexate (due to decreased renal clearance of methotrexate by anti-inflammatory agents in general and displacement of methotrexate from its plasma protein binding by salicylates). See [2 CONTRAINDICATIONS](#).

Methotrexate, used at 15mg/week or less: Salicylates may retard the elimination of methotrexate by decreasing renal clearance of methotrexate, displacing methotrexate from

protein binding sites, and thereby increasing its hematological toxicity.

Anti-coagulants, thrombolytics / other inhibitors of platelet aggregation / hemostasis, e.g. warfarin, heparin: Caution is necessary when salicylates and anticoagulants, thrombolytics / other inhibitors of platelet aggregation / hemostasis prescribed concurrently, as salicylates can depress the concentration of prothrombin in the plasma, leading to an increased risk of bleeding.

Oral hypoglycemics, e.g., Insulin, sulfonylureas: large doses of salicylates have a hypoglycemic action and may enhance the effect of oral hypoglycemic agents. Diabetics receiving concurrent salicylate and hypoglycemic therapy should be monitored closely: reduction of the sulfonylurea hypoglycemic drug dosage may be necessary.

Diuretics: Diuretics in combination with acetylsalicylic acid at higher doses leads to decreased glomerular filtration via decreased prostaglandin synthesis. As a result, sodium excretion may be decreased by salicylate administration.

Uricosuric Agents: Salicylates in large doses are uricosuric agents; smaller amounts may depress uric acid clearance and thus decrease the uricosuric effects of other drugs.

Valproic Acid: Salicylates may alter valproic acid (VPA) metabolism and may displace VPA from protein binding sites, possibly intensifying the effects of VPA. Caution is recommended when VPA is administered concomitantly with salicylates.

Glucocorticoids (systemic), except hydrocortisone used as replacement therapy in Addison's disease: Decreased blood salicylate levels during corticosteroid treatment and risk of salicylate overdose after this treatment is stopped via increased elimination of salicylates by corticosteroids. Concurrent use may increase the incidence of gastrointestinal bleeding and ulceration.

Angiotensin Converting Enzyme (ACE) Inhibitors: The hyponatremic and hypotensive effects of ACE inhibitors *may* be diminished by the concomitant administration of ASA due to its indirect effect on the renin-angiotensin conversion pathway (i.e., inhibition of vasodilatory prostaglandins leading to decreased glomerular filtration). The potential interaction may be related to the dose of ASA (3g/day or more).

Selective Serotonin Re-uptake Inhibitors (SSRIs): Increased risk of upper gastrointestinal bleeding due to possibly synergistic effect.

Digoxin: Plasma concentrations of digoxin are increased due to a decrease in renal excretion.

NSAIDs:

- **ASA and other NSAIDs:** The use of other NSAIDs with salicylates may increase the risk of ulcers and gastrointestinal bleeding due to a synergistic effect.
- **Ibuprofen:** Ibuprofen can interfere with the anti-platelet effect of low dose ASA acid (81-325 mg per day). Long-term daily use of ibuprofen may render ASA less effective

when used for cardioprotection and stroke prevention. To minimize this interaction, regular users of ibuprofen and of low-dose, immediate-release ASA should take the ibuprofen at least one hour after and 11 hours before the daily ASA dose. The use of delayed-release (e.g., enteric-coated) ASA is not recommended when using ibuprofen regularly.

- **Naproxen:** Naproxen may attenuate the irreversible platelet inhibition induced by acetylsalicylic acid. Clinical pharmacodynamic data suggest that concurrent (same day) naproxen sodium usage for more than one day consecutively inhibits the effect of low-dose acetylsalicylic acid on platelet activity and this inhibition may persist for up to several days after stopping naproxen sodium therapy. The clinical relevance of this interaction is not known. Treatment with naproxen, in patients with increased cardiovascular risk may limit the cardiovascular protection of acetylsalicylic acid (see *“Special warnings and precautions for use”*).

Healthcare professionals should advise consumers and patients regarding the appropriate concomitant use of NSAIDs (i.e., ibuprofen or naproxen) and ASA.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herb have not been established.

9.7 Drug-Laboratory Test Interactions

Salicylates can produce changes in thyroid function tests.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

ASA interferes with the production of prostaglandins in various organs and tissues through acetylation of the enzyme cyclo-oxygenase. Prostaglandins are themselves powerful irritants and produce headaches and pain on injection in man. Prostaglandins also appear to sensitize pain receptors to other noxious substances such as histamine and bradykinin. By preventing the synthesis and release of prostaglandins in inflammation, ASA may avert the sensitization of pain receptors.

The antipyretic activity of ASA is due to its ability to interfere with the production of prostaglandin E1 in the brain. Prostaglandin E1 is one of the most powerful pyretic agents known.

The inhibition of platelet aggregation by ASA is due to its ability to interfere with the production of thromboxane A2 within the platelet. Thromboxane A2 is, largely, responsible for the aggregating properties of platelets.

In vitro studies have shown that ASA enhances the activity of the Nitric oxide (NO)-cGMP system and heme oxygenase-1 (HO-1) by acting on endothelial NO synthase site.

10.2 Pharmacodynamics

Analgesia:

The analgesic effect of ASA has been recognized and utilized clinically for more than half a century. The degree of analgesia attained with ASA is moderate, but it has proved highly suitable in the management of pathological pain of mild to moderate severity. As regards site of action, both peripheral and CNS factors appear to contribute significantly to the pain relief afforded by ASA. As for mechanism of action, the accumulated evidence of recent years indicates that ASA acts by interfering with the synthesis and release of prostaglandins, thereby averting the sensitization of pain receptors to mechanical stimulation or to other mediators.

Antipyresis:

Interference with the synthesis and release of prostaglandins is also involved in the antipyretic activity of ASA. ASA effects a significant reduction in elevated body temperature, but has little effect on normal body temperature. This latter is maintained by a delicate balance between heat production and heat loss, with the hypothalamus regulating the set point at which body temperature is maintained. Fever is induced by synthesis and release of prostaglandins in this temperature-regulating area and ASA acts by interfering with this process. Heat production is not inhibited but dissipation of heat is augmented by increased peripheral blood flow and by sweating.

Anti-inflammatory effect:

Components of the anti-inflammatory action of the salicylates are increased capillary resistance, thus reducing capillary leakage in response to local toxins, interference with the production of tissue-destructive lysosomal enzymes and inhibition of the synthesis of prostaglandin E compounds which have been shown to be potent mediators of the inflammatory process. Besides interfering with the synthesis of prostaglandins ASA also acts by interfering with lymphocyte activation and lymphokine production. Lymphokines are produced by activated thymus lymphocytes which are abundant in the inflammatory tissues of patients suffering from rheumatoid arthritis. They cause increased vascular permeability and white blood cell chemotaxis, activate macrophages and stimulate lymphocyte DNA synthesis. They also induce release of tissue-destructive lysosomal enzymes as well as prostaglandins. The prostaglandins themselves, beside causing many manifestations of inflammation also act as a potent negative feedback mechanism by inhibiting lymphokine production. An in-depth review of the effects of ASA on the lymphocyte-macrophage axis in inflammation has been published.

Effects on platelets: relation to hemostasis and thrombosis.

Platelets play an important role in normal hemostasis and clinical pathologic and experimental evidence indicates that their aggregation may play an equally important role in the evolution of a variety of disease states including cerebrovascular disease, ischemic heart disease and myocardial infarction. ASA inhibits platelet aggregation by irreversibly acetylating platelet cyclo-oxygenase, thereby blocking the production of prostaglandin endoperoxides PGG₂ and PGH₂ which are precursors of the major platelet-aggregating material, thromboxane A₂, which is also a powerful vasoconstrictor. However, ASA does not prevent the adherence of platelets to damaged vessel walls or the release of granule contents from these adherent platelets. As the anuclear platelets are unable to synthesize new enzyme molecules to replace those that have been inactivated, inhibition of platelet aggregation by ASA thus persists for the life of the platelets. Daily administration of 20 to 40 mg of ASA to healthy volunteers reduced platelet thromboxane production but inhibited platelet aggregation only partially. When administered to patients recovering from myocardial infarction, 50 mg ASA daily had the same effects on thromboxane production, platelet aggregation and bleeding times as 324 mg daily. Other studies show that ASA doses of 40 to 325 mg daily suppressed thromboxane production by at least 80%, but 80 mg ASA daily was the lowest dose required for maximum cumulative thrombocyte function inhibition. The protective effect of ASA against experimentally induced thrombosis or atherosclerosis has been demonstrated in several animal models.

Besides inhibiting the biosynthesis of thromboxane A₂ by platelets, ASA also interferes with the production of prostacyclin (PGI₂) by vascular endothelial cells, the above-mentioned prostaglandin endoperoxides being common precursors of both thromboxane A₂ and prostacyclin. This latter compound is one of the most powerfully acting platelet deaggregators and vasodilators and thus it would appear that the interference with the hemostatic processes by ASA depends on the thromboxane-prostacyclin balance. In fact, it has been suggested that under some conditions, high doses of ASA may be thrombogenic. However, in contrast to platelets, the vascular endothelial cells are able to regenerate cyclo-oxygenase in a relatively short time and therefore therapeutic doses of ASA are likely to produce a lesser inhibition of the vascular prostacyclin system than of the platelet thromboxane-forming mechanism. In fact, there is no clinical evidence to indicate that high doses of ASA would result in an increased risk of thromboembolism. Indeed, quite the contrary was observed and, in a controlled study, paradoxical shortening of the bleeding time was not observed at a daily ASA dose of 3.6 g. Lower dosages of ASA make selective blocking of the TxA₂-synthesis without a simultaneous blocking of PGI₂-production possible.

The use of ASA in patients with a suspected acute myocardial infarction was investigated in a large multi-centre trial involving over 17,000 patients. Treatment with ASA resulted in a 23% reduction in the risk of vascular mortality versus placebo at 5 weeks. This use translates to a reduction of 24 deaths and 14 non-vascular events per 1000 patients treated.

The effect of time to therapy revealed that patients treated with ASA "early" (0 to 4 hours) versus "late" (5 to 24 hours) after symptom onset experienced reductions in the odds of vascular death of 25% versus 21%, versus placebo at 5 weeks. 'Early' treatment with ASA resulted in the saving of 4 additional lives per 1000 patients versus 'late' treatment.

Long term follow-up (up to 10 years) of patients in this study established that the early survival advantage to ASA persisted long term, and that this prolonged benefit was additive to that of fibrinolytic therapy.

The use of ASA for secondary prevention of thrombotic events is supported by a comprehensive overview of a number of clinical trials involving patients who already had some type of vascular disease (myocardial infarction, unstable angina, stroke or transient cerebral ischemia). Overall, these studies point to a 26-28 % reduction of the combined endpoints of MI, stroke, or vascular deaths by treatment with ASA alone at doses of 75 to 325 mg daily. Studies which directly compared low doses with higher doses (30-1200 mg/day), indicated that the incidence of gastrointestinal adverse effects were significantly less common with the lower doses.

In a study in patients undergoing coronary artery bypass surgery (CABG), patients given ASA at a dosage of 80 mg to 650 mg within 48 hours of revascularization had a risk of dying reduced to 1.3% as compared to 4.0% for those who did not receive treatment ($P < 0.001$). There was a reduction in the incidence of myocardial infarction of 2.8% vs. 5.4%, $p < 0.001$. In total, the reduction in fatal and non-fatal outcomes was lower in those who received ASA, 10.6% vs. 18.6% in those who did not ($p < 0.001$). The investigators Perioperative Ischemia Research Group (PIRG) concluded that early use of ASA after coronary by-pass surgery is safe and is associated with a reduce risk of death and ischemic complications involving the heart, brain, kidneys and gastrointestinal tract.

There was no ASA dose effect observed for either fatal or non-fatal outcomes with total doses lower than 325mg daily.

Recent discussions have focused on the efficacy of ASA for the primary prevention of myocardial infarction and stroke. Two large scale randomized trials, aimed at evaluating prophylactic use of ASA, were conducted among apparently healthy male physicians (22,000 in the United States and 5,000 in the United Kingdom) and their results have been published. In the summary overview of the combined results presented by the principal investigators, the authors state that:

“Taken together, these two primary prevention studies demonstrate a significant ($p < 0.0001$) reduction in non-fatal myocardial infarction of about one third.”

On the other hand, the same two studies have not indicated any reduction in overall vascular mortality and also suggested a slight increase in the risk of non-fatal disabling stroke. Current controversy exists about the applicability of these findings, obtained in a selected population, to the general public. As well, the optimum dosage regimen still remains an open question in this regard. Thus, the use of ASA for primary prevention should remain, in the words of the principal investigators:

"a matter of judgment in which the physician considers the cardiovascular risk profile of the patient and balances the known hazards of ASA...against the clearly established reduction in the incidence of a first myocardial infarction".

Effect of Ibuprofen on Platelet Aggregation, Bleeding and Clotting Times in Normal Volunteers.

Experimental data suggest that ibuprofen may inhibit the effect of low dose ASA (81-325 mg per day) on platelet aggregation when they are dosed concomitantly. In one study, when a single dose of ibuprofen 400mg was taken within 8 hours before or within 30 minutes after immediate release ASA dosing (81mg), a decreased effect of acetylsalicylic acid on the formation of thromboxane or platelet aggregation occurred. However, the limitations of these data and the uncertainties regarding extrapolation of *ex vivo* data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use. In a more recent double blind, randomized, placebo-controlled trial with healthy subjects by Cryer et. al, 2005, it has been shown that the drug-drug interaction is absent when immediate release ASA (81 mg) was taken 1 hour before taking ibuprofen (400 mg, TID) and also when ibuprofen was given 11 hours before the intake of low dose ASA. Thus, in order to adequately minimize potential interaction, the recommended dosing schedule for immediate release low dose ASA is to wait at least 11 hours after or 1 hour before taking up to a 400mg dose of ibuprofen.

10.3 Pharmacokinetics

Absorption:

When ASA is taken orally, it is rapidly absorbed from the stomach and proximal small intestine. The gastric mucosa is permeable to the non-ionized form of acetylsalicylic acid, which passes through the stomach wall by a passive diffusion process.

Optimum absorption of salicylate in the human stomach occurs in the pH range of 2.15 to 4.10. Absorption in the small intestine occurs at a significantly faster rate than in the stomach. After an oral dose of 0.65g ASA, the plasma acetylsalicylate concentration in man usually reaches a level between 0.6 and 1.0mg % in 20 minutes after ingestion and drops to 0.2 mg % within an hour. Within the same period of time, half or more of the ingested dose is hydrolyzed to salicylic acid by esterases in the gastrointestinal mucosa and the liver, the total plasma salicylate concentration reaching a peak between one or two hours after ingestion, averaging between 3 and 7mg %. Many factors influence the speed of absorption of ASA in a particular individual at a given time; tablet disintegration, solubility, particle size, gastric emptying time, psychological state, physical condition, nature and quantity of gastric contents, etc., all affect absorption.

Distribution:

Distribution of salicylate throughout most body fluids and tissues proceeds at a rapid rate after absorption. Aside from the plasma itself, fluids which have been found to contain substantial amounts of salicylate after oral ingestion include spinal, peritoneal and synovial fluids, saliva and milk. Tissues containing high concentrations of the drug are the kidney, liver, heart and lungs. Concentrations in the brain are usually low, and are minimal in feces, bile and sweat. The drug readily crosses the placental barrier. At clinical concentrations, from 50% to 90% of the salicylate is bound to plasma proteins especially albumin, while acetylsalicylic acid itself is bound to only a very limited extent. However, ASA has the capacity of acetylating various

proteins, hormones, DNA, platelets and hemoglobin, which at least partly explains its wide-ranging pharmacological actions.

Metabolism:

The liver appears to be the principal site for salicylate metabolism, although other tissues may also be involved. The three chief metabolic products of ASA or salicylic acid are salicyluric acid, the ether or phenolic glucuronide and the ester or acyl glucuronide. A small fraction is also converted to gentisic acid and other hydroxybenzoic acids. The half-life of ASA in the circulation is from 13 to 19 minutes so that the blood level drops quickly after absorption is complete. However, the half-life of the salicylate ranges between 3.5 and 4.5 hours, which means that 50% of the ingested dose leaves the circulation within that time.

Elimination:

Excretion of salicylates occurs principally via the kidney, through a combination of glomerular filtration and tubular excretion, in the form of free salicylic acid, salicyluric acid, as well as phenolic and acyl glucuronides. Salicylate can be detected in the urine shortly after its ingestion but the full dose requires up to 48 hours for complete elimination. The rate of excretion of free salicylate is extremely variable, reported recovery rates in human urine ranging from 10% to 85%, depending largely on urinary pH. In general, it can be stated that acid urine facilitates reabsorption of salicylate by renal tubules, while alkaline urine promotes excretion of the drug.

With the administration of 325mg, elimination of ASA is linear following a first order kinetics. At high concentrations, elimination half life increases.

Special Populations and Conditions

Absorption and clearance of salicylates are not affected by gender or age.

11 STORAGE, STABILITY AND DISPOSAL

ENTROPHEN: Store between 15°C and 30°C.

12 SPECIAL HANDLING INSTRUCTIONS

None

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: acetylsalicylic acid

Chemical name: 2-(Acetyloxy) benzoic acid; salicylic acid acetate

Molecular formula and molecular mass: $C_9H_8O_4$, 180.16

Structural formula:



Physicochemical properties:

Description: White granules, commonly tabular or needle-like, or white crystalline powder. Odourless or having a faint odour.

Solubility: Slightly soluble in water; freely soluble in alcohol; soluble in chloroform and ether; sparingly soluble in absolute ether.

pK value (25°C): 3.49

Melting Point: 135°C (rapid heating)

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

Table 2 - Summary of patient demographics for clinical trials in reducing the risk of vascular mortality in patients with a suspected acute myocardial infarction

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
ISIS – 2 ISIS, 1998	Multicentre international 2x2 factorial, randomized, placebo controlled study.	160-162.5 mg oral for 30 days after suspected acute MI. (Median follow-up to 15 months).	ASA 8587, Streptokinase 8592, ASA + Strep 4292, Placebo 4300	Not available	Not available

Table 3 - Summary of patient demographics for clinical trials in reducing the risk of a first non-fatal myocardial infarction in individuals deemed to be at sufficient risk of such an event by their physician

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
TPT Medical Research Council's General Practice Research Framework, 1998	Randomized, factorial, placebo-controlled, parallel-group study	warfarin (mean) 4.1mg, ASA 75mg	warfarin + ASA 1,277 warfarin + ASA placebo 1,268 ASA + warfarin placebo 1,268 ASA placebo + warfarin placebo 1,272	45-69 years	Male
HOT Hansson et al, 1998	Prospective, randomized, open with blinded endpoint evaluation (PROBE). ASA component was double blinded	ASA 75mg or placebo; felodipine 5mg, ACE-inhibitors, β -blockers, diuretics mean - 3.8 years	19,567 subjects of which 18,790 were randomized to ASA or Placebo (ASA = 9,399; Placebo = 9,391)	61.5 years - mean (50-80 years)	Male 53% Female 47%

Table 4 - Summary of patient demographics for clinical trials in reducing the risk of morbidity and death in patients with unstable angina and in those with previous myocardial infarction

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
RISC 1990	Prospective randomized, double blind, placebo controlled, multicentre study	ASA 75mg daily for 3 months after initial heparin by IV for 5 days	- Heparin 198 - ASA 189 - Heparin + ASA 210 - Placebo 199	58 years	Male
RISC Trial, 12 month follow-up 1990	Prospective randomized, double blind, placebo controlled, multicentre study	ASA 75mg daily for 3 months after initial IV heparin for 5 days	- Heparin 198 - ASA 189 - Heparin + ASA 210 - Placebo 199	58 years	Male
Verheugt et al. 1990	Prospective, randomized, placebo-controlled, comparative multicentre study	ASA 100mg for approx. 3 months	ASA 50 Placebo 50	ASA 61 years Placebo 64 years	ASA 72% male Placebo 76% male
SAPAT 1992	Prospective, randomized, double blind placebo controlled, multicentered study	ASA 75mg daily for up to 6 years (median 50 months)	ASA 1009 Placebo 1026	52 years	ASA male 51% Placebo males 53%

Table 5 - Summary of patient demographics for clinical trials in reducing the risk of transient ischemic attacks (TIA) and for secondary prevention of atherothrombotic cerebral infarction

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
SALT 1991	Prospective, randomized, double blind, placebo controlled, multicentre study	ASA 75mg daily for minimum of 12 months and maximum of 63 months (mean 30.6 months)	ASA 676 Placebo 684	50-79 years ASA mean: 67 years PLA mean: 66.8 years	ASA 65.4% male Placebo 66.2% male
Lindblad et al. 1993	Prospective, randomized, double blind placebo controlled study	ASA 75mg daily for 6 months	ASA 117 Placebo 115	66 years (40-81 years)	75% male

14.2 Study Results

Table 6 - Results of ISIS-2 Study in reducing the risk of vascular mortality in patients with a suspected acute myocardial infarction.

Primary Endpoints	Associated value and statistical significance for Drug at specific dosages	Associated value and statistical significance for Placebo or active control
Vascular death after 5-week period	ASA 9.4%, Placebo 11.8% Odds reduction 23%	ASA vs. Placebo 2p < 0.00001 ASA was statistically significantly better than placebo

Table 7 - Results of studies; TPT, HOT in reducing the risk of a first non-fatal myocardial infarction in individuals deemed to be at sufficient risk of such an event by their physician

Primary Endpoints	Associated value and statistical significance for Drug at specific dosages	Associated value and statistical significance for Placebo or active control
<p>Study: TPT</p> <p>All ischemic heart disease defined as the sum of fatal and non-fatal events (i.e. coronary death and fatal and non-fatal myocardial infarction).</p>	<p>ASA 10.2%, Placebo 13.3%</p> <p>20% reduction in IHD</p>	<p>p = 0.04</p> <p>ASA was statistically significantly better than placebo</p>
<p>Study: HOT</p> <p>Major cardiovascular events were defined as all (fatal and non-fatal) myocardial infarctions, all (fatal and non-fatal) strokes, and all other cardiovascular deaths.</p>	<p>Reduction in all cardiovascular events by 15 % and all myocardial infarction by 36%</p>	<p>p=0.03</p> <p>p = 0.002</p> <p>ASA was statistically significantly better than placebo</p>

Table 8: Results of studies; RISC, RISC Trial 12-month follow-up, Verheugt et al & SAPAT in reducing the risk of morbidity and death in patients with unstable angina and in those with previous myocardial infarction

Primary Endpoints	Associated value and statistical significance for Drug at specific dosages	Associated value and statistical significance for Placebo or active control
<p>Study: RISC</p> <p>Death or non-fatal MI</p>	<p>5 days: Risk Ratio 0.43 (CI 0.21-0.91)</p> <p>30 days: Risk Ratio 0.31 (CI 0.18-0.53)</p> <p>90 days: Risk Ratio 0.36 (0.21-0.57)</p>	<p>p=0.03</p> <p>p<0.0001</p> <p>p<0.0001</p> <p>ASA was statistically significantly better than placebo</p> <p>ASA vs Comparator:</p> <p>Heparin was not statistically significantly better than placebo and there was no comparison to ASA</p>

Study: RISC Trial 12-month follow-up MI and death	6 months: ASA-35 events, heparin 76 events. Risk Ratio 0.46 (CI 0.31- 0.67) 12 months, ASA 44 events, heparin 85 events. Risk Ratio 0.52 (CI 0.37-0.72)	p<0.0001 p=0.0001 ASA was statistically significantly better than placebo
Study: Verheugt et al. Reinfarction rate	ASA 2 patients (4%), Placebo 9 patients (18%)	p<0.03 ASA was statistically significantly better than placebo
Study: SAPAT non-fatal or fatal MI or sudden death	ASA 8%, Placebo 12%	p=0.003 ASA was statistically significantly better than placebo

Table 9 - Results of studies; SALT & Linblad et al in reducing the risk of transient ischemic attacks (TIA) and for secondary prevention of atherothrombotic cerebral infarction

Primary Endpoints	Associated value and statistical significance for Drug at specific dosages	Associated value and statistical significance for Placebo or active control
SALT Risk of stroke or death	18 % reduction in risk: Relative Risk 0.82 (CI 0.67-0.99)	p=0.02 ASA was statistically significantly better than placebo
Lindblad et al Stroke (without complete recovery) at 6 months	ASA 2 cases, Placebo 11 cases	p=0.01 ASA was statistically significantly better than placebo

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

The clinical and pathological signs of poisoning from toxic and lethal oral doses of ASA have been extensively described for man, much less extensively for other species.

The acute toxicity of ASA in animals has been studied and reviewed in detail by Boyd. The signs of poisoning in rats from doses in the lethal range are due to varying degrees of gastroenteritis, hepatitis, nephritis, pulmonary edema, encephalopathy, shock and minor toxic effects on other organs and tissues. Death is due to convulsions or cardiovascular shock. The major difference between species appears to be the ability to vomit toxic doses seen in man, cats and dogs, but not in mice, rats and rabbits. Otherwise, the pathological reaction to toxic

doses of ASA is similar in all species in which such studies have been reported. The acute oral LD₅₀ values have been reported as being over 1.0 g/kg in man, cat and dog, 0.92 g/kg in female and 1.48 g/kg in male albino rats, 1.19 g/kg in guinea pig, 1.1 g/kg in mouse and 1.8 g/kg in rabbit.

Chronic toxicity studies were reported in mice and rats. When ASA was administered at 2 to 20 times the maximum tolerated clinical dose to mice for up to one year, a dose-related deleterious effect was observed on mean survival time, number of young born and number of young raised to weaning age. No evidence of carcinogenic effect was found.

The chronic oral LD₅₀ in male albino rats has been reported as 0.24 g/kg/day when given for 100 days. At these daily doses ASA produced no anorexia and no loss of body weight. It did produce polydipsia, aciduria, diuresis, drowsiness, hyperreflexia, piloerection, rapid and deep respiration, tachycardia, and during the second month, soft stools, epistaxis, sialorrhea, dacryorrhea and death in hypothermic coma. Autopsy disclosed the presence of a hypertrophied stomach, renal congestion, mild hepatitis and pneumonitis. While teratogenic effects were noted in animals at near lethal doses, there is no evidence to indicate that ASA is teratogenic in man.

17 SUPPORTING PRODUCT MONOGRAPHS

ASPIRIN® Regular Strength tablets 325 mg, ASPIRIN® Extra Strength tablets 500 mg, ASPIRIN® 81 mg tablets, ASPIRIN® 81 mg Quick Chews® tablets 81 mg, submission control 280158, Product Monograph, Bayer Inc., (JUL 15, 2024)

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

ENTROPHEN[®]

Acetylsalicylic acid delayed release tablets

81 mg

Read this carefully before you start taking **ENTROPHEN**. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **ENTROPHEN**.

Serious Warnings and Precautions

- **Risk in Pregnancy:** Talk to your doctor if you are trying to conceive, in your first or second trimester of pregnancy or if breastfeeding.

What is ENTROPHEN used for?

- ENTROPHEN is for doctor supervised long-term preventive therapy.
- ENTROPHEN may help save your life if you think you are having a heart attack.

How does ENTROPHEN work?

ENTROPHEN belongs to a group of medicines called antiplatelet drugs. Platelets are very small structures in blood, smaller than red or white blood cells, which clump together during blood clotting. By preventing this clumping, antiplatelet drugs reduce the chances of blood clots forming.

USE DURING A HEART ATTACK

If you think you are having a heart attack, call 911 immediately then, chew and swallow two ENTROPHEN tablets. It is important to chew the product, to ensure this medicine works quickly. Then get to a hospital immediately for medical attention. Inform the emergency services / hospital that you have taken ENTROPHEN. Taking ENTROPHEN, at the first signs and symptoms can reduce your risk of dying from a heart attack.

The signs and symptoms of a heart attack include:

- uncomfortable pressure, fullness, squeezing or pain in the centre of the chest that lasts more than a few minutes, or goes away quickly and comes back
- pain that spreads to the shoulders, neck or arms
- chest discomfort with lightheadedness, fainting, sweating, nausea or shortness of breath

Chest pain is the most common symptom in both sexes, but women may also experience other symptoms such as unusual fatigue that gets worse with activity, difficulty of breathing, heartburn/nausea and /or vomiting unrelieved by antacids, tightening and pain in the chest

that may extend into the neck, jaws and shoulders, general feeling of weakness, paleness, sweating.

At the hospital, the doctor will then recommend appropriate therapy.

What are the ingredients in ENTROPHEN?

Medicinal ingredients: acetylsalicylic acid (ASA)

Non-medicinal ingredients: Colloidal Silicon Dioxide, Glyceryl Stearate, Lactose Anhydrous, Methacrylic Acid Copolymer, Methylated Silica, Methylcellulose, Polydimethylsiloxane, Polysorbate 65, Pregelatinized Starch, Sodium Bicarbonate, Sodium Lauryl Sulphate, Sorbic Acid, Stearic Acid, Sulfuric Acid, Talc, Titanium Dioxide and Triethyl Citrate.

ENTROPHEN comes in the following dosage forms: Delayed release tablets 81mg

Do not use ENTROPHEN if you:

- are taking other products containing ASA, salicylates or NSAIDs / pain relievers / fever reducers
- are allergic to ASA, salicylates, non-steroidal anti-inflammatory drugs (NSAIDs)/pain relievers/fever reducers or other ingredients in the product. Allergic reactions may appear as hives, difficulty breathing, shock, skin reddening, rash or blisters, swelling of the face or throat, or sudden collapse.
- have an ulcer, history of ulcers or are prone to bleeding
- have active or severe liver or kidney disease or congestive heart failure
- have a history of asthma caused by salicylates or other NSAIDs
- are using methotrexate at doses of 15mg/week or more
- are in the last trimester of pregnancy because it may cause problems in the unborn child or complications during delivery

STOMACH BLEEDING WARNING: contains a NSAID which **may cause severe stomach bleeding**. The symptoms are fainting, vomit blood, have bloody or black stools, have stomach pain that does not get better.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take ENTROPHEN. Talk about any health conditions or problems you may have, including if you have/are:

- asthma, high blood pressure, heart disease, gout or other serious conditions
- age 60 years or older
- stomach problems such as heartburn
- impaired liver/kidney or impaired cardiovascular circulation (renal vascular disease, congestive heart failure, volume depletion, major surgery, sepsis or major hemorrhagic events)
- having 3 or more alcoholic drinks per day
- history of blood clotting defects
- severe anemia

- severe glucose-6-phosphate dehydrogenase (G6PD) deficiency
- trying to conceive or breast-feeding
- will be having surgery in five to seven days

Other warnings you should know about:

- The use of NSAIDs, like ENTROPHEN, in the second trimester of pregnancy should be restricted to the lowest dose necessary for shortest possible duration.
 - At 20 weeks or later in pregnancy, your use of ENTROPHEN may need to be monitored by a doctor due to the rare risk of narrowing of a blood vessel in the heart or kidney problems in the unborn baby, which may result in decreased amniotic fluid volume and other complications.
- **CAUTION:** Contains enough drug to seriously harm a child; **KEEP OUT OF THEIR REACH. DO NOT GIVE** to children/teenagers less than 18 years of age who have chicken pox or cold/flu symptoms before a doctor is consulted about Reye’s Syndrome, a rare serious illness reported to be associated with ASA.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with ENTROPHEN:

- blood thinners
- acetaminophen
- anticonvulsants
- anti-diabetic/arthritis/gout medicines
- digoxin
- glucocorticoids
- methotrexate
- selective serotonin re-uptake inhibitors (a type of antidepressants)
- diuretics
- ACE inhibitors (medication for high blood pressure)
- Do not use NSAIDs (i.e. ibuprofen or naproxen) if you are taking ENTROPHEN for preventive therapy without talking to a doctor or pharmacist, as NSAIDs may interfere with the preventive benefits of ENTROPHEN.

How to take ENTROPHEN:

- For doctor supervised long-term preventive therapy you should take this medicine at the same time every day. This will help you to remember to take your medication. For maximum effectiveness, it is very important to take ENTROPHEN *every day* as directed by your doctor. Do not take more tablets than your doctor recommends. Your doctor may tell you to take ENTROPHEN with other medications; he or she may also tell you to eat special foods, exercise or take other steps to safeguard your health. ENTROPHEN tablets have a special *enteric coating*, which allows them to pass undissolved through the stomach and into the intestine. By dissolving in the intestine rather than the stomach, the risk of stomach upset is reduced. Therefore, to maintain this protection, the tablets should not be crushed or broken.

Can I Continue to Take ENTROPHEN for Relief of Headache, Fever or Arthritis Pain?

- ENTROPHEN is specially designed for doctor supervised long-term preventive therapy. It is a smaller dose than you would need to take for a headache or other types of pain and is unlike other pain reliever products such as acetaminophen or NSAIDs e.g., ibuprofen, naproxen. Ask your doctor or pharmacist about other ENTROPHEN products available (or other pain relievers such as acetaminophen, ibuprofen, naproxen or salicylates) and the correct dosage for the relief of your headache, fever or arthritic pain. Always consult with your doctor or pharmacist before taking other medications.

Usual dose:

Adults ≥ 18 years: For doctor supervised long-term preventive therapy: 1 to 4 tablets daily, depending on your doctor's instructions. During a heart attack: Call 911, then, chew 2 tablets.

Overdose:

If you think you, or a person you are caring for, have taken too much ENTROPHEN contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed Dose:

If you forget to take your medication, take it when you remember. But do not take extra medication to compensate for a missed dosage unless instructed by your doctor.

What are possible side effects from using ENTROPHEN?

Like all medicines, ENTROPHEN may occasionally produce unwanted side effects. You should call your doctor if you experience: nausea, vomiting; stomach irritation, or pain; if you notice that you are 'bruising' more easily than you were before starting a daily dose of ENTROPHEN. Regular daily use of alcohol while on ENTROPHEN daily therapy may increase your risk of developing gastrointestinal bleeding.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Loss of hearing			✓
Ringing or buzzing in ears			✓
Bleeding in ears			✓
Feel faint/dizzy			✓
Skin rash			✓
Itching			✓
Bloody vomit			✓
Vomit that looks like coffee grounds			✓
Bright red blood in stools			✓
Black or tarry stools			✓
Stomach pain that does not get better			✓
Hives			✓
Swelling of eyes, face, lips, tongue, or throat			✓
Wheezing or breathing difficulties			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store between 15-30°C. Keep out of reach and sight of children.

If you want more information about ENTROPHEN:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) or the manufacturer's website www.pendopharm.com, or by calling 1-888-550-6060.

This leaflet was prepared by Pendopharm, division of Pharmascience Inc.

Date of Authorization: February 25, 2025

ENTROPHEN® is a registered trademark owned by Norwell Consumer Healthcare Inc.